| Caduet Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Caduet 5 mg-20 mg | tablet | oral | 1.0 each | OTC |
| Caduet 2.5 mg-20 mg | tablet | oral | 1.0 each | OTC |
| Caduet 10 mg-20 mg | tablet | oral | 1.0 each | OTC |
| Caduet 5 mg-40 mg | tablet | oral | 1.0 each | OTC |
| Caduet 5 mg-80 mg | tablet | oral | 1.0 each | OTC |
| Caduet 10 mg-20 mg | tablet | oral | 1.0 each | OTC |
Posted by normameagher over 2 years ago
depression, sick feeling, drowsiness, confusion, stomach pains, you name it, I have it.
Posted by carla54 over 2 years ago
ankles swelling
Pfizer says may win six Japan approvals this year - Reuters
The US drug maker is also hopeful that it will get the green light for Caduet, a combination drug of high blood pressure medicine Norvasc and cholesterol ...
Thu Feb 28 01:39:02 -0500 2008
African Americans Shown to Benefit From Single Pill for Blood ... - Diabetes Health (press release)
Researchers sponsored by Pfizer studied the effects of Pfizer's Caduet, a single pill that contains the drugs amlodipine and atorvastatin, used to lower ...
Wed Feb 20 06:20:26 -0500 2008
African Americans Shown to Benefit From Single Pill for Blood ... - Diabetes Health (press release)
all 2 news articles
Wed Feb 20 06:20:26 -0500 2008
amlodipine besylate - The besylate salt of amlodipine, a synthetic, dihydropyridine, calcium channel blocker with antihypertensive and antianginal effects. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries,decreases myocardial contractility, increases blood flow and oxygen delivery to the myocardial tissue and decreases total peripheral resistance. This agent may also modulate multi-drug response (MDR) activity through inhibition of the p-glycoprotein efflux pump.
atorvastatin - The calcium salt form of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)